7 research outputs found
Comparison between a new multiplex electrochemiluminescence assay and the WHO reference enzyme-linked immunosorbent assay to measure serum antibodies against pneumococcal serotype-specific polysaccharides
BACKGROUND: Two electrochemiluminescence (ECL) assays were developed which, together, can simultaneously measure serum antibodies against pneumococcal capsular polysaccharides (PnPS) for 17 serotypes. The assays were validated for the 13 PnPS included in the 13-valent pneumococcal conjugate vaccine (PCV13). As recommended by the World Health Organization (WHO), we compared the ECL assays with the WHO reference enzyme-linked immunosorbent assay (ELISA) and derived a threshold corresponding to the 0.35 µg/mL threshold established for the WHO reference ELISA for the non-inferiority comparison and licensure of new PCVs against invasive pneumococcal disease. METHODS: A panel of 452 serum samples from children vaccinated with one of the three licensed PCVs was assessed with the ECL assays and the WHO reference ELISA. The ECL assay threshold for the aggregated seven PnPS included in the 7-valent PCV (PCV7) and serotype-specific thresholds were determined using a receiver operating characteristics (ROC) curve-based approach and Deming regression. To evaluate concordance between the ECL assays and the WHO reference ELISA, serostatus agreement rates between both assays and geometric means of the ratios (GMRs) of concentrations obtained with both assays were calculated. RESULTS: The thresholds for the seven aggregated PCV7 serotypes obtained with the ROC curve-based approach and Deming regression approximated 0.35 µg/mL (0.38 and 0.34 µg/mL, respectively). Individual thresholds for the PCV13 serotypes ranged between 0.24 and 0.51 µg/mL across both approaches. Serostatus agreement rates using a 0.35 µg/mL threshold for both assays were ≥86.9% for all PCV13 serotypes. GMRs ranged between 0.85 and 1.25 for 11/13 serotypes and were <1.29 for the two remaining serotypes. CONCLUSION: The ECL assays were comparable to the WHO reference ELISA and offer a sensitive, time- and serum volume-saving method to quantify serotype-specific anti-PnPS antibodies in pediatric sera. A 0.35 µg/mL threshold will be used for each PCV13 serotype to assess PCV immunogenicity in clinical trials
Characterization of a Human Antibody Fragment Fab and Its Calcium Phosphate Nanoparticles that Inhibit Rabies Virus Infection with Vaccine
Recombinant antibody phage display technology has been used to mimic many aspects
of the processes that govern the generation and selection of high-affinity
natural human antibodies in the human immune system, especially for infectious
disease prophylaxis. An anti-rabies virus immunized phage-display Fab library
was constructed from peripheral blood lymphocytes from vaccinated volunteers.
The immunized antibody library, with a diversity of 6.7×108,
was used to select and produce antibodies that bound to rabies virus
glycoprotein. After five rounds of immobilized fixed rabies virion panning, four
unique DNA sequences were found in the higher binding clones, and only one,
Fab094, showed neutralization activity. Fab094 components were analyzed by
ELISA, immunoprecipitation and immunofluorescent staining. ELISA and
immunofluorescence showed that Fab094 bound specifically to rabies virions.
Immunoprecipitation and mass spectrometry showed that Fab094 reacted with rabies
virus glycoprotein. To improve the penetration power of Fab094 antibodies, we
developed Fab094 calcium phosphate nanoparticles (Fab094-CPNPs) and tested their
efficacy. The rapid fluorescent focus inhibition test indicated that the
neutralizing antibody titers of Fab094 and Fab094-CPNPs were reached at 200.17
IU/Kg and 246.12 IU/Kg, respectively. These findings were confirmed in vivo in a
Kunming mouse challenge model. Our results demonstrate that human Fab094 and
Fab094-CPNPs are efficacious candidate drugs to replace rabies immunoglobulin in
post-exposure prophylaxis (PEP)
More Accurate Insight into the Incidence of Human Rabies in Developing Countries through Validated Laboratory Techniques
International audienceNo abstract availabl